This is the authors' abstract. We don't add key points for this paper.
In patients with renal impairment ( n = 22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations ( r 2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Souza et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: